Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018
LEXINGTON, Mass., Jan. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics, will participate in a panel entitled "IO on the Move: New Targets, New Trends, New Combinations" on Wednesday, January 10,, 2018 at 9:00-10:00 am P.T. at the 10th Annual Biotech Showcase™ at the Hilton San Francisco Union Square.
Dr. John Castle is a pioneer in translational bioinformatics and genomics and leader in the identification of immune-inducing antigens for cancer therapy. At Agenus, Dr. Castle will drive the application of mutational and biochemical based neoantigens for the development and evaluation of effective cancer treatments.
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Dr. Castle's participation in an upcoming panel and his anticipated contributions to Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Jennifer Buell, PhD
SOURCE Agenus Inc.